New hope for Hard-to-Treat colorectal cancer? denikitug trial launches
NCT ID NCT07527858
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This phase 2 trial tests a new drug called denikitug, alone or combined with other treatments, in 170 people with advanced microsatellite stable (MSS) colorectal cancer. MSS colorectal cancer is a common type that often does not respond to standard immunotherapy. The study aims to see if denikitug can shrink tumors and improve outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Denikitug (also called GS-1811), given alone or with nivolumab, trifluridine-tipiracil, or bevacizumab
What this could lead to
If successful, this could offer a new treatment option for people with advanced MSS colorectal cancer, a type that typically does not respond to immunotherapy.
What could go wrong
This is an early phase 2 trial with a small number of participants. The drug may not shrink tumors or improve survival, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MICROSATELLITE STABLE COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Avera Cancer Institute
RECRUITINGSioux Falls, South Dakota, 57105, United States
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
-
Chris O'Brien Lifehouse
RECRUITINGCamperdown, CA, 2050, Australia
-
Dana-Farber Cancer Institute
ACTIVE_NOT_RECRUITINGBoston, Massachusetts, 02215, United States
-
Peter MacCallum Cancer Centre
RECRUITINGMelbourne, Victoria, 3000, Australia
-
Royal Brisbane and Women's Hospital
RECRUITINGHerston, Queensland, 4029, Australia
-
University of Virginia,
RECRUITINGCharlottesville, Virginia, 22908, United States
-
Yale-New Haven Hospital - Yale Cancer Center
RECRUITINGNorth Haven, Connecticut, 06473 2195, United States